ClinicalTrials.Veeva

Menu

Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.

U

Universitair Ziekenhuis Brussel

Status

Unknown

Conditions

Severe Asthma
COPD

Treatments

Device: In-check Dial device (Clement Clarke International Ltd, Harlow, UK)

Study type

Interventional

Funder types

Other

Identifiers

NCT03377920
143201733083

Details and patient eligibility

About

The main aim is to study correlations between Peak inspiratory flow measured during a spirometry (PIFspiro) and Peak inspiratory flow measured over a pre-set resistance (PIFresist) in COPD patients and severe asthma patients. PIFresist will be measured using 5 different resistances, representing all DPI's relevant for the treatment of obstructive lung diseases. If this shows a distinct relationship between PIFspiro and PIFresist, PIFspiro cut-off points will be sought in an attempt to predict which patients are likely to be able to produce optimal flows for DPI use. If successful, this will make the actual measurement of PIFresist redundant in clinical practice. Also the relationship between PIFresist and device internal resistance in addition to PIFspiro (which corresponds to a very low resistance) will be examined.

Full description

The correct use of dry powder inhalers (DPI) crucially depends on the peak inspiratory flow (PIF) that the patient can generate when overcoming internal resistance of the inhaler device.

It has been shown that some patients cannot achieve sufficient peak inspiratory flows with some DPI's, especially in the elderly population. The In-check Dial device (Clement Clarke International Ltd, Harlow, UK) allows to measure these inspiratory flows for different pre-set resistances, representing different DPI's.

Study design: interventional, single center, single visit study

30 Severe asthmatics and 70 COPD patients will be recruited in the UZ Brussel respiratory outpatient clinic.

All participants will provide written informed consent.

Patients will perform:

  • pre-bronchodilator spirometry for the measurement of PIFspiro as per European respiratory Society/American Thoracic Society (ERS/ATS) guidelines for standard lung function5 (part of routine clinical follow-up).
  • 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's

Enrollment

100 estimated patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Severe asthmatics (M/F; > 20 y) entering the Belgian Severe Asthma Registry (BSAR)
  • COPD patients (GOLD stage II-IV; M/F; > 40 y)

Exclusion criteria

  • Inability to perform spirometry

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

Severe asthma patients; COPD patients
Experimental group
Description:
Cross sectional study Lung function measurement
Treatment:
Device: In-check Dial device (Clement Clarke International Ltd, Harlow, UK)

Trial contacts and locations

1

Loading...

Central trial contact

Shane Hanon

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems